Zepbound (tirzepatide, made by Eli Lilly) is FDA-approved for two conditions: chronic weight management in adults with obesity or overweight plus a weight-related condition, and moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. Unlike its sister drug Mounjaro, Zepbound carries no Type 2 diabetes indication, and that single fact drives most insurance denials, because many payers still treat GLP-1 drugs prescribed for weight loss differently than the same molecule prescribed for diabetes.
Whether your plan pays for Zepbound in 2026 depends on three things: which type of insurance you have (Medicare, Medicaid, employer plan, or ACA marketplace), which FDA-approved indication your doctor documents (obesity or sleep apnea), and whether your plan's formulary and prior authorization rules are satisfied. This guide walks through each payer type with 2026 figures. For the full Medicare-specific breakdown, see does Medicare cover Zepbound. For retail pricing detail, see Zepbound cost without insurance.
Coverage Breakdown
| Insurance Type | Zepbound for Obesity | Zepbound for Sleep Apnea (OSA) | Notes |
|---|---|---|---|
| Medicare Part D / Medicare Advantage | Partial (GLP-1 Bridge only) | Partial (plan-dependent) | GLP-1 Bridge Program covers the KwikPen formulation at $50/month starting July 1, 2026; standard Part D excludes weight-loss agents by statute |
| Medicaid (state programs) | Varies by state (~13 states) | Rarely, state-dependent | Obesity coverage is optional for states; about 13 state Medicaid programs cover GLP-1s for obesity in 2026, down from 16 in 2025 |
| Commercial / employer-sponsored | Yes, at large employers | Yes, more consistently | About 43% of employers with 5,000-plus workers cover weight-loss GLP-1s in 2026 (64% at 20,000-plus); only 19% of employers with 200 to 999 workers do |
| ACA Marketplace plans | Rarely (about 9% of carriers) | Varies, plan-dependent | Weight-loss drugs are not an Essential Health Benefit under the ACA, so only about 26 of roughly 300 Marketplace carriers in 9 states cover Zepbound for obesity in 2026 |
Zepbound has no FDA-approved Type 2 diabetes indication, so it never qualifies for the same diabetes-drug coverage pathway that applies to Mounjaro (also tirzepatide, made by Eli Lilly). Coverage for the obesity indication is governed by each payer's own formulary decisions because federal law lets Medicare Part D and Medicaid treat anti-obesity agents as an optional benefit. Coverage for the sleep apnea indication is generally easier to obtain because OSA is a recognized medical condition rather than a weight-loss exclusion, though plan-by-plan variation is still wide.
Source: FDA Zepbound Prescribing Information 2026, CMS Medicare GLP-1 Bridge, KFF Medicaid GLP-1 Coverage Tracker 2026, KFF ACA Marketplace GLP-1 Coverage Analysis 2026
Direct Answer: Coverage Depends on Insurer, Diagnosis, and State
It depends. Zepbound (tirzepatide) is FDA-approved for chronic weight management and sleep apnea, not diabetes, so coverage hinges on your insurer, diagnosis, and state. Employer plans cover it most often, roughly 43% of large employers in 2026. Medicare covers it via the GLP-1 Bridge Program or for sleep apnea. Only about 13 state Medicaid programs cover it for obesity, and just 26 of 300 ACA marketplace carriers cover it nationwide.
Medicare Coverage of Zepbound in 2026
Original Medicare Part D historically excluded Zepbound for weight loss under a statutory ban on anti-obesity agents (Social Security Act Section 1927(d)(2)(A)). That changed on a limited basis when CMS launched the Medicare GLP-1 Bridge Program on July 1, 2026, which covers the Zepbound KwikPen formulation for obesity at a $50 per month copay for eligible beneficiaries who meet BMI and comorbidity criteria. That $50 copay sits outside the standard Part D benefit and does not count toward the 2026 Part D out-of-pocket cap of $2,100. Single-dose vial and single-dose pen formulations of Zepbound are not part of the Bridge Program.
Separately, because Zepbound is also FDA-approved for obstructive sleep apnea, standard Part D plans may cover it when a prescriber documents the OSA diagnosis (ICD-10 code G47.33) rather than obesity, since OSA is not a statutorily excluded condition. Medicare Advantage plans can also add Zepbound as a supplemental benefit independent of the Bridge Program. Because the Medicare rules are the most detailed of any payer type, see the full breakdown at does Medicare cover Zepbound for BMI thresholds, formulary tiers, and Extra Help interactions.
Medicaid Coverage of Zepbound by State in 2026
Medicaid treats anti-obesity drugs as an optional benefit under the same type of statutory exclusion that applies to Medicare Part D, so coverage of Zepbound for weight management varies sharply by state. As of 2026, roughly 13 state Medicaid programs cover GLP-1 drugs for obesity under fee-for-service, down from 16 states in 2025 as several states, including Pennsylvania, California, and South Carolina, restricted or ended adult obesity-drug coverage in the past year citing cost pressure. States that still cover weight-loss GLP-1s typically require documented BMI, prior authorization, and participation in a lifestyle-modification program.
The CMS BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) Model is a new federal initiative that could expand Medicaid access to GLP-1 obesity drugs starting as early as May 2026, with states applying to participate through January 2027. Participation is voluntary, so beneficiaries in non-participating states will not see new obesity-drug coverage from this model. Because Medicaid rules differ so widely, always confirm current coverage directly with your state Medicaid agency or managed care plan before assuming a denial is final. For full state detail, see does Medicaid cover GLP-1 drugs by state.
Commercial and Employer-Sponsored Insurance Coverage in 2026
Commercial and employer-sponsored plans are the most likely payer to cover Zepbound, and coverage scales with employer size. About 43% of companies with 5,000 or more employees cover GLP-1 medications like Zepbound for weight loss in 2026, rising to roughly 64% among employers with 20,000-plus workers, but only about 19% of employers with 200 to 999 employees include weight-loss drug coverage. Large self-insured employers set their own benefit design under ERISA rather than state insurance law, which explains most of this variation. Coverage for the sleep apnea indication tends to be more consistent across employer sizes because OSA is treated as a standard medical diagnosis rather than a cosmetic or lifestyle exclusion.
Even where coverage exists, more than 88% of patients with a covered benefit still face a prior authorization requirement, typically documenting BMI of 30 or higher (or 27 with a weight-related condition such as hypertension or sleep apnea). Effective January 1, 2026, several large insurers, including some Blue Cross Blue Shield plans, tightened or dropped GLP-1 weight-loss coverage, limiting it to diabetes indications or plans with an explicit weight-management rider. Check your plan's Summary of Benefits and Coverage or call the number on your insurance card to confirm current-year formulary status before assuming coverage is unchanged from last year.
ACA Marketplace Plans and Zepbound in 2026
The Affordable Care Act does not classify weight-loss medications as an Essential Health Benefit, so ACA marketplace insurers are free to exclude Zepbound for obesity, and most do. As of 2026, only about 26 of roughly 300 marketplace carriers cover a GLP-1 weight-loss drug, and those plans are concentrated in just 9 states; North Dakota is currently the only state that requires marketplace plans to cover obesity medications. Marketplace enrollees with access to GLP-1 obesity coverage fell from about 3.6 million in 2024 to roughly 2.8 million in 2026 as carriers scaled back benefit designs to control premium growth.
Coverage for Zepbound prescribed for obstructive sleep apnea on marketplace plans is not tracked as separately as the obesity indication, but tends to be somewhat more available because insurers classify OSA treatment differently from weight-management benefits. Enrollees should check a plan's Summary of Benefits and Coverage document during open enrollment (November 1, 2025 through January 15, 2026 for 2026 coverage) and specifically search the formulary for tirzepatide before selecting a plan if GLP-1 access matters to your household.